Fresenius Kabi Introduces Dexmedetomidine Hydrochloride Injection

Lake Zurich, Ill., November 30, 2015 – Global health care company Fresenius Kabi announced today it has introduced Dexmedetomidine Hydrochloride Injection in the United States. The drug is available immediately in 200mcg (base) per 2mL single dose vials.

Fresenius Kabi Dexmedetomidine Hydrochloride Injection was approved by the U.S. Food and Drug Administration in September. It is therapeutically equivalent to Precedex™.

“Dexmedetomidine is a welcome addition to our anesthesia portfolio, further enhancing the breadth and depth of the medications we provide for sedation in hospital and surgery-center settings,” said John Ducker, president and CEO of Fresenius Kabi USA.

Dexmedetomidine Hydrochloride Injection, a relatively selective alpha2-adrenergic agonist, is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.

About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.

Precedex™ is a registered trademark of Orion Corporation.

Contacts
Matt Kuhn
847-550-5751
matt.kuhn@fresenius-kabi.com